Listed

Prelude Therapeutics Inc

PRLDNasdaqCIK 1678660HealthcareFiscal year ends Dec 31

Reports and events: 115 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Prelude Therapeutics Inc, Reports and events
FiledFormWhat it isAccession number
2024-02-1516:22 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-24-015913
2023-12-1316:55 ETSC 13D/AOwnership report, active investor, amended0001104659-23-125744
2023-12-1109:17 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-069210
2023-11-0116:37 ET10-QQuarterly reportPeriod 2023-09-300000950170-23-057523
2023-11-0116:23 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000950170-23-057481
2023-08-0308:14 ET10-QQuarterly reportPeriod 2023-06-300000950170-23-037611
2023-08-0308:10 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-202314
2023-06-2116:05 ET8-K5.07 Shareholder vote results0001193125-23-171145
2023-06-0116:25 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-23-025712
2023-05-2416:47 ETSC 13D/AOwnership report, active investor, amended0000947871-23-000625
2023-05-2416:31 ETSC 13D/AOwnership report, active investor, amended0001104659-23-064148
2023-05-1916:06 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-149304
2023-05-1716:03 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-146980
2023-05-0808:11 ET10-QQuarterly reportPeriod 2023-03-310000950170-23-018478
2023-05-0808:06 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-23-018477
2023-04-2808:46 ETDEF 14AProxy statementPeriod 2023-06-160000950170-23-015497
2023-03-1516:38 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-23-071400
2023-03-1508:53 ET10-KAnnual reportPeriod 2022-12-310000950170-23-007989
2023-03-1508:31 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0000950170-23-007983
2023-02-1411:14 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-23-002729
2023-01-2316:16 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0000950170-23-001023
2023-01-0908:01 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-23-000439
2022-11-1408:27 ET10-QQuarterly reportPeriod 2022-09-300000950170-22-024732
2022-11-1408:21 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000950170-22-024727
2022-08-0908:12 ET10-QQuarterly reportPeriod 2022-06-300001564590-22-028596
2022-08-0908:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-22-028595
2022-06-2108:00 ET8-K5.07 Shareholder vote results0001564590-22-023674
2022-05-1008:11 ET10-QQuarterly reportPeriod 2022-03-310001564590-22-019085
2022-05-1008:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-22-019084
2022-04-2907:59 ETDEF 14AProxy statementPeriod 2022-06-170001564590-22-016626
2022-04-0816:30 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-100388
2022-03-1708:11 ET10-KAnnual reportPeriod 2021-12-310001564590-22-010723
2022-03-1608:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-22-010534
2022-03-0908:22 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-22-070007
2022-02-1617:03 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-22-044450
2022-01-1007:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-22-005032
2021-12-0309:00 ET8-K1.01 Entry into a material agreement0001193125-21-347333
2021-11-1208:28 ET10-QQuarterly reportPeriod 2021-09-300001564590-21-056509
2021-11-1207:57 ET8-K2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001564590-21-056478
2021-09-1708:32 ET8-K5.02 Departure or appointment of officers or directors0001193125-21-275680
2021-08-1210:41 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-043724
2021-08-1210:36 ET10-QQuarterly reportPeriod 2021-06-300001564590-21-043718
2021-07-1916:53 ET8-K5.02 Departure or appointment of officers or directors0001193125-21-218690
2021-06-2216:02 ET8-K5.07 Shareholder vote results0001193125-21-196185
2021-05-1209:01 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-21-158457
2021-05-1108:15 ET10-QQuarterly reportPeriod 2021-03-310001564590-21-026308
2021-05-1108:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-026296
2021-04-2916:05 ETDEF 14AProxy statementPeriod 2021-06-180001193125-21-140361
2021-03-1709:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-21-083591
2021-03-1608:20 ET10-KAnnual reportPeriod 2020-12-310001564590-21-013330

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.